Who
David Silberman
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Compugen; Chief Financial Officer, Oramed Pharmaceuticals.
In numbers
- Trades disclosed
- 12
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Sep 2021
- Last trade
- 29 Jul 2026
- Last filed
- 30 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jul 2026filed 30 Jul 2026 | CGEN CompugenBiotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 29 Jul 2026filed 30 Jul 2026 | CGEN Compugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 29 Jul 2026filed 30 Jul 2026 | CGEN Compugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 29 Jul 2026filed 30 Jul 2026 | CGEN CompugenBiotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 4 Jan 2024filed 8 Jan 2024 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —136,500 | filing |
| 26 May 2023filed 31 May 2023 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,500 | filing |
| 17 Apr 2023filed 20 Apr 2023 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —97,500 | filing |
| 28 Jul 2022filed 1 Aug 2022 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —39,000 | filing |
| 3 Jan 2022filed 5 Jan 2022 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —19,000 | filing |
| 1 Sep 2021filed 2 Sep 2021 | ORMP Oramed Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Sep 2021filed 2 Sep 2021 | ORMP Oramed PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
Alan Kaplinsky, Jason Brown, David Silberman on CFPB Reccomendatinatlawreview.com · 10 Sep 2026
1 headline in the last 90 days name David Silberman; no company of theirs resolves to a name we track.
Sectors
No trade we could place in a sector.